Preclinical evaluation of the synthetic adjuvant SQS-21 and its constituent isomeric saponins. - Wikidata - wikimedia - TriplyDB

Preclinical evaluation of the synthetic adjuvant SQS-21 and its constituent isomeric saponins.

Preclinical evaluation of the synthetic adjuvant SQS-21 and its constituent isomeric saponins.

http://www.wikidata.org/entity/Q33899683

about

Development of Improved Vaccine Adjuvants Based on the Saponin Natural Product QS-21 through Chemical Synthesis New vaccines against influenza virus.The saponins: polar isoprenoids with important and diverse biological activities.Characterization of in vivo anti-rotavirus activities of saponin extracts from Quillaja saponaria Molina.Synthesis and preclinical evaluation of QS-21 variants leading to simplified vaccine adjuvants and mechanistic probes Tau-Directed Immunotherapy: A Promising Strategy for Treating Alzheimer's Disease and Other Tauopathies.Natural and synthetic saponin adjuvant QS-21 for vaccines against cancer.Synthesis of QS-21-based immunoadjuvants.Quillaja Saponin Variants with Central Glycosidic Linkage Modifications Exhibit Distinct Conformations and Adjuvant Activities Chemistry and biology of oligovalent β-(1→2)-linked oligomannosides: new insights into carbohydrate-based adjuvants in immunotherapy.

P2860

Q28829361-D0C21B83-594A-4A72-8B75-EBF37BC3BF65 Q30357932-B8E1EA40-7FA9-4847-83BB-7DABBE9D91E0 Q33902446-D5983907-1DFD-41AE-A1C9-659F59A8F8D2 Q35019757-1596F533-5DE3-4A00-97AC-54D6D57C53AE Q36216866-BAA032BF-9127-4FD7-B26D-E1A18089A64A Q36558485-9972450E-EC68-4871-9BB4-0136BA2D4350 Q36856279-CE8CFDE0-EE9E-41FA-8DD1-1B737EA7F818 Q37608887-8FB05889-29AB-4DFB-A9B5-C85916586B0E Q39236688-FC298F6B-1CFD-4163-9085-470E45B69190 Q43635984-A78CAFA6-0879-42D4-8584-DC4293F35514

P2860

Preclinical evaluation of the synthetic adjuvant SQS-21 and its constituent isomeric saponins.

http://www.wikidata.org/entity/Q33899683

description

2010 nî lūn-bûn

@nan

2010 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Preclinical evaluation of the ...... constituent isomeric saponins.

@ast

Preclinical evaluation of the ...... constituent isomeric saponins.

@en

type

label

Preclinical evaluation of the ...... constituent isomeric saponins.

@ast

Preclinical evaluation of the ...... constituent isomeric saponins.

@en

prefLabel

Preclinical evaluation of the ...... constituent isomeric saponins.

@ast

Preclinical evaluation of the ...... constituent isomeric saponins.

@en

P1433

Q33899683-AD9DA746-A746-4F00-B329-BE1D6DDC41CF

P1476

Q33899683-9803E744-EBC6-4A1B-941B-46A0858A1F3E

P2093

Q33899683-088E1D7C-91CF-496E-B1EF-F3B6D9547BC2

Q33899683-1D5663A1-A49B-4AD3-9897-968DA06BA53B

Q33899683-20A65715-29FE-4257-A68A-3CC74B00CC49

Q33899683-222E0BBD-D5A0-4869-92C7-7427A40F881E

Q33899683-7D3E27B6-27B8-440D-8FB0-254AB584F04F

Q33899683-90B5AD2A-5BA6-4089-8468-8A96087FD40D

Q33899683-9283116D-D5E9-4FAB-87F1-2544B3EAAE46

Q33899683-967A1112-EE18-4BB0-858D-2548C254323F

P2860

Q33899683-0E153353-E65F-4B02-8F67-433F93F77FD7

Q33899683-104AEF3C-E1FC-40F5-A226-61C6F5782CE2

Q33899683-31ADB5E4-3ADC-4DD1-81EC-C6B273D3DB79

Q33899683-39C393A5-2748-405C-96F5-4462058A1E70

Q33899683-3DDD8107-3F86-487C-8E6D-C0B0455E79EC

Q33899683-58E8C0E7-B062-4459-AABA-5FB241809AC5

Q33899683-84426A65-B5F1-45C3-BBF0-B222938F4518

Q33899683-8D6D0591-0C04-45B7-85EB-893B289F8B5F

Q33899683-9B71AD90-908C-4A3C-9C56-9886BE9C3958

Q33899683-B5150C16-08A5-46E8-A265-C104D789DD54

P304

Q33899683-63C4B8A0-B1B5-4167-97B2-8A0FFED10834

P31

Q33899683-67FECCB3-1C24-42C5-98E1-9C9F4880D51B

P356

Q33899683-7DFDD3E7-2FF4-4E2C-8BC7-5367C5ACF522

P407

Q33899683-9E609686-2918-4F45-B485-F8DC8092CFF4

P433

Q33899683-0665D543-0DD1-41B3-B510-6286F9818064

P478

Q33899683-8AA846DD-B717-4BAF-B4D0-74400C103201

P577

Q33899683-AFB8083F-A30A-47CD-A961-202F2A9FB105

P5875

Q33899683-30B20CEA-97F3-4FA1-943E-136EE299E74A

P698

Q33899683-9EB1FBF1-8E0D-4424-9F77-2B043312B6D1

P932

Q33899683-D8011E70-80B1-4F1A-89DA-668EB65D70A5

P356

J.VACCINE.2010.04.034

P1433

P1476

Preclinical evaluation of the ...... constituent isomeric saponins.

@en

P2093

Constantine George

http://www.w3.org/2001/XMLSchema#string

David Y Gin

http://www.w3.org/2001/XMLSchema#string

Govind Ragupathi

http://www.w3.org/2001/XMLSchema#string

Jianfeng Hang

http://www.w3.org/2001/XMLSchema#string

Kai Deng

http://www.w3.org/2001/XMLSchema#string

Michelle M Adams

http://www.w3.org/2001/XMLSchema#string

Payal Damani

http://www.w3.org/2001/XMLSchema#string

Philip O Livingston

http://www.w3.org/2001/XMLSchema#string

P2860

Induction of systemic and mucosal immune responses to human immunodeficiency virus type 1 by a DNA vaccine formulated with QS-21 saponin adjuvant via intramuscular and intranasal routes.

Synthesis of QS-21-xylose: establishment of the immunopotentiating activity of synthetic QS-21 adjuvant with a melanoma vaccine.

Cancer vaccines targeting carbohydrate antigens.

Phase 1 trial of immunological adjuvant QS-21 with a GM2 ganglioside-keyhole limpet haemocyanin conjugate vaccine in patients with malignant melanoma.

Induction of antibodies against GD3 ganglioside in melanoma patients by vaccination with GD3-lactone-KLH conjugate plus immunological adjuvant QS-21.

Synthetic studies of complex immunostimulants from Quillaja saponaria: synthesis of the potent clinical immunoadjuvant QS-21Aapi.

Studies on the synthesis of landomycin A: synthesis and glycosidation reactions of L-rhodinosyl acetate derivatives.

Potent, long lasting systemic antibody levels and mixed Th1/Th2 immune response after nasal immunization with malaria antigen loaded PLGA microparticles.

Safety, tolerability and immunogenicity of new formulations of the Plasmodium falciparum malaria peptide vaccine SPf66 combined with the immunological adjuvant QS-21.

Synthesis of the potent immunostimulatory adjuvant QS-21A.

P304

4260-4267

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.VACCINE.2010.04.034

http://www.w3.org/2001/XMLSchema#string

P407

P433

26

http://www.w3.org/2001/XMLSchema#string

P478

28

http://www.w3.org/2001/XMLSchema#string

P577

2010-05-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

44581041

http://www.w3.org/2001/XMLSchema#string

P698

20450868

http://www.w3.org/2001/XMLSchema#string

P932

2882175

http://www.w3.org/2001/XMLSchema#string